Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It mainly develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's development programs include Disc/Spine Program which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells, collected from the patient's bone marrow; and Metabolic Program which include development of a cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Melville, NY, 11747